Clinical Trial Update: Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of cabozantinib for hepatocellular carcinoma progressing after first-line immuno-oncology therapy; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING